# US 6,727,074 B2 · Alzheimer's disease secretase, APP substrates therefor, and uses therefor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,727,074 B2
- Document ID: US6727074B2
- Status: Granted
- Kind: B2
- Application number: 09/794,927
- Filed: 2001-02-27
- Published: 2001-08-23
- Granted: 2004-04-27
- Earliest claimed: 1998-09-24
- Assignees: Pharmacia & Upjohn Company
- Inventors: Mark E. Gurney; Michael J. Bienkowski; Robert L. Heinrikson; Luis A. Parodi; Riqiang Yan
- Web page: https://patentgrep.com/patent/US6727074B2

## CPC

- C12N 9/6478: {Aspartic endopeptidases (3.4.23)}
- C07K 14/4711: {Alzheimer's disease; Amyloid plaque core protein}
- C12Q 1/37: involving peptidase or proteinase
- C07K 2319/00: Fusion polypeptide
- C12N 2799/026: where the vector is derived from a baculovirus
- G01N 2333/96472: Aspartic endopeptidases (3.4.23)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention provides the enzyme and enzymatic procedures for cleaving the β secretase cleavage site of the APP protein and associated nucleic acids, peptides, vectors, cells and cell isolates and assays. The invention further provides a modified APP protein and associated nucleic acids, peptides, vectors, cells, and cell isolates, and assays that are particularly useful for identifying candidate therapeutics for treatment or prevention of Alzheimer's disease.

## Claims

### Claim 1

A method for identifying an agent that modulates the activity of Asp2 aspartyl protease, comprising the steps of:
(a) contacting an Asp2 aspartyl protease with an amyloid precursor protein (APP) in the presence and absence of a test agent, wherein the Asp2 aspartyl protease is a recombinant polypeptide that exhibits Asp2 aspartyl protease activity involved in processing APP into amyloid beta and is expressed by a host cell transformed or transfected with a nucleic acid molecule that encodes the polypeptide and that hybridizes under the following stringent hybridization conditions to the complement of SEQ ID NO: 3:
(1) hybridization at 42° C. in a hybridization buffer comprising 6×SSC and 0.1% SDS, and
(2) washing at 65° C. in a wash solution comprising 1×SSC and 0.1% SDS;
(b) determining the APP processing activity of the Asp2 aspartyl protease in the presence and absence of the test agent; and
(c) comparing the APP processing activity of the Asp2 aspartyl protease in the presence of the test agent to the APP processing activity in the absence of the test agent to identify an agent that modulates the activity of the Asp2 aspartyl protease, wherein a modulator that is an Asp2 inhibitor reduces APP processing and a modulator that is an Asp2 agonist increases such processing.

### Claim 2 (depends on 1)

The method of claim 1 wherein the amyloid precursor protein is a human isoform of APP.

### Claim 3 (depends on 1)

The method of claim 1 wherein the amyloid precursor protein comprises the APP β-secretase cleavage site that comprises the Swedish mutation (K→N, M→L).

### Claim 4 (depends on 1)

The method of claim 1 wherein the amyloid precursor protein comprises a carboxy-terminal di-lysine (KK).

### Claim 5 (depends on 1)

A method according to claim 1, wherein the amyloid precursor protein is expressed byte cell.

### Claim 6

A method for identifying an agent that inhibits the APP processing activity of a protease, comprising the steps of:
(a) contacting a protease with an amyloid precursor protein (APP) substrate in the presence and absence of a test agent,
wherein the protease comprises the recombinant polypeptide expressed by a cell transformed or transfected with a nucleic acid that comprises a nucleotide sequence encoding the protease, and
wherein the protease comprises an amino acid sequence at least 95% identical to the Asp2 amino acid sequence set forth in SEQ ID NO: 4 or a fragment thereof that includes the aspartyl protease active site tripeptides DTG and DSG and exhibits Asp2 aspartyl protease activity involved in processing APP into amyloid beta;
(b) determining the proteolytic processing activity of the protease toward the APP substrate in the presence and absence of the test agent; and
(c) comparing the proteolytic processing activity of the protease in the presence of the test agent to the activity in the absence of the test agent to identify an agent that inhibits the APP processing activity of the protease, wherein reduced activity in the presence of the test agent identifies an agent that inhibits the APP processing activity of the protease.

### Claim 7 (depends on 6)

A method according to claim 6 wherein the protease comprises the Asp2 aspartyl protease amino acid sequence set forth in SEQ ID NO: 4 or a fragment thereof that exhibits Asp2 protease activity involved in processing APP into amyloid beta,
wherein said fragment is a contiguous fragment that includes the aspartyl protease active site tripeptides DTG and DSP and exhibits Asp2 aspartyl protease activity involved in processing APP into amyloid beta.

### Claim 8 (depends on 6)

A method according to claim 6 wherein the protease comprises the Asp2 amino acid sequence of SEQ ID NO: 4.

### Claim 9

A method for identifying an agent that inhibits the APP processing activity of a protease, comprising the steps of:
(a) contacting a protease with an amyloid precursor protein (APP) substrate in the presence and absence of a test agent,
wherein the protease comprises the recombinant polypeptide that exhibits Asp2 protease activity involved in processing APP into amyloid beta and is expressed by a cell transformed or transfected with a nucleic acid that comprises a nucleotide sequence encoding the protease, said nucleotide sequence hybridizing under the following stringent hybridization conditions to the complement of the nucleotide sequence set forth in SEQ ID NO: 3:
(1) hybridization at 42° C. in a hybridization buffer comprising 6×SSC and 0.1% SDS, and
(2) washing at 65° C. in a wash solution comprising 1×SSC and 0.1% SDS;
(b) determining the proteolytic processing activity of the protease toward the APP substrate in the presence and absence of the test agent; and
(c) comparing the proteolytic processing activity of the aspartyl protease in the presence of the test agent to the activity in the absence of the test agent to identify an agent that inhibits the APP processing activity of the protease, wherein reduced activity in the presence of the test agent identifies an agent that inhibits the APP processing activity of the protease.

### Claim 10 (depends on 6, 7, 8, 9)

A method according to any one of claims 6-8 or 9, wherein the APP substrate comprises an APP β-secretase cleavage site that comprises the Swedish mutation (K→N, M→L).

### Claim 11 (depends on 6, 7, 8, 9)

A method according to any one of claims 6-8 or 9, wherein the APP substrate comprises an amyloid beta (A-beta) processing site.

### Claim 12 (depends on 6, 7, 8, 9)

A method according to any one of claims 6-8 or 9, wherein the APP substrate is a fluorogenic or chromogenic substrate.

### Claim 13 (depends on 6, 9)

A method according to claims 6 or 9, wherein the APP substrate comprises an APP polypeptide expressed by the cell.

### Claim 14 (depends on 1, 6, 9)

A method according to any one of claims 1, 6 and 9, wherein the protease of step (a) is purified and isolated.

### Claim 15 (depends on 1, 6, 9)

A method according to any one of claims 1, 6 and 9, wherein the contacting step comprises growing the transformed or transfected cell that expresses the protease in the presence and absence of the test agent.

### Claim 16 (depends on 6, 7, 8, 9)

A method according to any one of claims 6-8 or 9, wherein the APP substrate comprises a carboxy-terminal di-lysine (KK).

### Claim 17 (depends on 14)

A method according to claim 14, wherein the protease is substantially free of other proteases.

### Claim 18 (depends on 15)

A method according to claim 15, wherein the cell comprises a vector that comprises the nucleic acid.

### Claim 19 (depends on 15)

A method according to claim 15, wherein the determining step comprises measuring the production of amyloid beta peptide by the cell in the presence and absence of the test agent.

### Claim 20 (depends on 13)

A method according to claim 13, wherein the host cell is a human embryonic kidney cell line 293 (HEK293) cell.

### Claim 21

A method for identifying an agent that inhibits the APP processing activity of a protease, comprising the steps of:
(a) contacting a protease with an amyloid precursor protein (APP) substrate in the presence and absence of a test agent,
wherein the protease comprises the recombinant polypeptide expressed by a cell transformed or transfected with a nucleic acid that comprises a nucleotide sequence encoding the protease, and
wherein the protease comprises an amino acid sequence at least 95% identical to the Asp2 amino acid sequence set forth in SEQ ID NO: 4 or a fragment thereof that includes the aspartyl protease active site tripeptides DTG and DSG and exhibits Asp2 aspartyl protease activity involved in processing APP into amyloid beta;
wherein the APP substrate is a peptide comprising a β-secretase cleavage site that comprises the formula P2-P1-P1′-P2′ (SEQ ID NO: 74), wherein
P2 is an amino acid selected from K and N;
P1 is an amino acid selected from M and L;
P1′ is the amino acid D; and
P2′ is the amino acid A,
(b) determining the proteolytic processing activity of the protease toward the APP substrate in the presence and absence of the test agent; and
(c) comparing the proteolytic processing activity of the protease in the presence of the test agent to the activity in the absence of the test agent to identify an agent that inhibits the APP processing activity of the protease, wherein reduced activity in the presence of the test agent identifies an agent that inhibits the APP processing activity of the protease.

### Claim 22

A method for identifying an agent that inhibits the APP processing activity of a protease, comprising the steps of:
(a) contacting a protease with an amyloid precursor protein (APP) substrate in the presence and absence of a test agent,
wherein the protease comprises the recombinant polypeptide that exhibits Asp2 protease activity involved in processing APP into amyloid beta and is expressed by a cell transformed or transfected with a nucleic acid that comprises a nucleotide sequence encoding the protease, said nucleotide sequence hybridizing under the following stringent hybridization conditions to the complement of the nucleotide sequence set forth in SEQ ID NO: 3:
(1) hybridization at 42° C. in a hybridization buffer comprising 6×SSC and 0.1% SDS, and
(2) washing at 65° C. in a wash solution comprising 1×SSC and 0.1% SDS;
wherein the APP substrate is a peptide comprising a β-secretase cleavage site that comprises the formula P2-P1-P1′-P2′ (SEQ ID NO: 74), wherein
P2 is an amino acid selected from K and N;
P1 is an amino acid selected from M and L;
P1′ is the amino acid D; and
P2′ is the amino acid A,
(b) determining to proteolytic processing activity of the protease toward the APP substrate in the presence and absence of the test agent; and
(c) comparing the proteolytic processing activity of the aspartyl protease in the presence of the test agent to the activity in the absence of the test agent to identify an agent that inhibits the APP processing activity of the protease, wherein reduced activity in the presence of the test agent identifies an agent that inhibits the APP processing activity of the protease.

### Claim 23 (depends on 21, 22)

A method according to claim 21 or 22, wherein the peptide comprises the amino acid sequence KMDA (SEQ ID NO: 64, positions 4-7).

### Claim 24 (depends on 21, 22)

A method according to claim 21 or 22, wherein the peptide comprises the amino acid sequence EVKMDAEF (SEQ ID NO: 67).

### Claim 25 (depends on 21, 22)

A method according to claim 21 or 22, wherein the peptide comprises the amino acid sequence NLDA (SEQ ID NO: 66).

### Claim 26 (depends on 21, 22)

A method according to claim 21 or 22, wherein the peptide comprises the amino acid sequence SEVNLDAEFR (SEQ ID NO: 63).
